CHIESI USA INC
BiotechCHIESI USA INC is a biotechnology company focused on Immunology.
FDA Novel Drug Designations
(2018)See 1 novel approval →
CHIESI USA INC's Key Drugs
CHIESI USA INC's core commercial portfolio centers on REVCOVI, spanning Immunology — its most strategically important drugs approved in the last 15 years.
CHIESI USA INC's Recent FDA Approvals
New NDA/BLA approvals for CHIESI USA INC over the last two years — novel drugs only, excluding generics and label supplements.
CHIESI USA INC's Therapeutic Areas
CHIESI USA INC's approved drugs and pipeline span 1 therapeutic area, led by Immunology, across 1 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
CHIESI USA INC's Top Competitors
CHIESI USA INC's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Novartis, and AbbVie. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
CHIESI USA INC Pipeline Snapshot
Active clinical trials for CHIESI USA INC across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • REVCOVI leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Immunology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 1999-11-18
- Latest
- 2021-05-17
- Applications
- 2